Loading...
Market
What will be the median overall survival reported in the next major clinical trial results for advanced melanoma immunotherapy by end of 2024?
2
Resolution / Starting Odds
Less than 50 months • 25%
50-60 months • 25%
60-70 months • 25%
More than 70 months • 25%
Clinical trial publications and announcements at medical conferences
Story
CheckMate 067: Decade of Immunotherapy Advances Boosts Advanced Melanoma Survival to 72 Months
Sep 16, 2024, 12:30 PM
A decade of advancements in immunotherapy has significantly improved survival rates for patients with advanced melanoma. The CheckMate 067 trial revealed that the combination of nivolumab and ipilimumab resulted in a median overall survival of 72 months, compared to 37 months with nivolumab alone and 20 months with ipilimumab alone. The trial results were presented at the European Society for Medical Oncology (ESMO) 2024 conference. Merck presented 10-year follow-up data for their immunotherapy, highlighting the long-term benefits in metastatic melanoma survival. The medical community, including Weill Cornell, acknowledges the progress but emphasizes that further work is needed. The double drug treatment raises survival rate for half of advanced melanoma to 10 years.
View original story
Similar markets
PFS < 6 months • 25%
PFS 6-8 months • 25%
PFS 8-10 months • 25%
PFS > 10 months • 25%
Yes • 50%
No • 50%
Significant tumor shrinkage • 25%
Improved survival rates • 25%
No significant effect • 25%
Other • 25%
Significant Improvement • 33%
No Change • 33%
Significant Adverse Effects • 34%
0-10% • 25%
11-20% • 25%
21-30% • 25%
More than 30% • 25%
0%-10% • 25%
10%-20% • 25%
20%-30% • 25%
More than 30% • 25%
Yes • 50%
No • 50%
Successful with significant results • 25%
Moderate success with some positive results • 25%
No significant results • 25%
Trial halted or inconclusive • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Positive - Significant survival improvement • 25%
Neutral - No significant difference • 25%
Negative - Worse outcomes • 25%
Trial inconclusive • 25%